The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs

Journal of Pharmaceutical Sciences

Volumn 87, Issue 9, 1998, Pages 1025-1040

  Kusuhara, Hiroyuki ^a   Suzuki, Hiroshi ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; COLCHICINE; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DOMPERIDONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; IVERMECTIN; LOPERAMIDE; METHOTREXATE; MITOXANTRONE; MORPHINE; ONDANSETRON; PACLITAXEL; PHENYTOIN; QUINIDINE; STEROID; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANION TRANSPORT; BILIARY EXCRETION; CANCER COMBINATION CHEMOTHERAPY; DETOXIFICATION; DRUG EXCRETION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; INTRAHEPATIC BILE DUCT; MOLECULAR CLONING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SHORT SURVEY; XENOBIOTIC METABOLISM;

EID: 0031691234     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970100b     Document Type: Article

References (191)

1. Dano, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 1973, 323, 466-483.
2. Skovsgaard, T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978, 38, 1785-1791.
3. Higgins, C. F. ABC transporters: From microorganisms to man. Annu. Rev. Cell Biol. 1992, 8, 67-113.
4. Bellamy, W. T. P-glycoproteins and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 161-183.
5. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
6. Gottesman, M. M.; Hrycyna, C. A.; Schoenlein, P. V.; Germann, U. A.; Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 1995, 29, 607-649.
7. Gottesman, M. M.; Pastan, I.; Ambudkar, S. V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 1996, 6, 610-617.
8. Oude Elferink, R. P. J.; Meijer, D. K. F.; Kuipers, F.; Jansen, P. L. M.; Groen, A. K.; Groothuis, G. M. M. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1995, 1241, 215-268.
9. Safa, A. R. In Principles of Antineoplasmic drug development and pharmacology; Schilsky, R. L.; Milano, G. A.; Ratain, M. J., Ed.; Marcel Dekken Inc.: New York, 1996; pp 457-486.
10. Loe, D. W.; Deeley, R. G.; Cole, S. P. C. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 1996, 32A, 945-957.
11. Lautier, D.; Canitrot, Y.; Deeley, R. G.; Cole, S. P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 1996, 52, 967-977.
12. Ueda, K.; Okamura, N.; Hirai, M.; Tanigawara, Y.; Saeki, T.; Kioka, N.; Komano, T.; Hori, R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 1992, 267, 24248-24252.
13. Kusuhara, H.; Suzuki, H.; Terasaki, T.; Kakee, A.; Lemaire, M.; Sugiyama, Y. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J. Pharmacol. Exp. Ther. 1997, 283, 574-580.
14. van Asperen, J.; Schinkel, A. H.; Beijnen, J. H.; Nooijen, W. J.; Borst, P.; van Tellingen, O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J. Natl. Cancer Inst. 1996, 88, 994-999.
15. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P.; Berns, A. J. M.; Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
16. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; Borst, P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 1995, 96, 1698-1705.
17. Schinkel, A. H.; Wagenaar, E.; Mol, C. A. A. M.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97, 2517-2524.
18. Schinkel, A. H.; Mayer, U.; Wagenaar, E.; Mol, C. A. A. M.; van Deemter, L.; Smit, J. J. M.; van der Valk, M. A.; Voordouw, A. C.; Spits, H.; van Tellingen, O.; Zijlmans, J. M. J. M.; Fibbe, W. E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4028-4033.
19. Mayer, U.; Wagenaar, E.; Beijnen, J. H.; Smit, J. W.; Meijer, D. K.; van Asperen, J.; Borst, P.; Schinkel, A. H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 1996, 119, 1038-1044.
20. Sparreboom, A.; van Asperen, J.; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K.; Borst, P.; Nooijen, W. J.; Beijnen, J. H.; van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2031-2035.
21. Loo, T. W.; Clarke, D. M. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 1994, 33, 14049-14057.
22. Safa, A. R.; Stern, R. K.; Choi, K.; Agresti, M.; Tamai, I.; Mehta, N. D.; Roninson, I. B. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185- - - -Val-185 substitution in P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7225-7229.
23. Rao, U. S. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J. Biol. Chem. 1995, 270, 6686-6690.
24. Taguchi, Y.; Morishima, M.; Komano, T.; Ueda, K. Amino acid substitutions in the first transmembrane domain (TM1) of P-glycoprotein that alter substrate specificity. FEBS Lett. 1997, 413, 142-146.
25. Norris, M. D.; De Graaf, D.; Haber, M.; Kavallaris, M.; Madafiglio, J.; Gilbert, J.; Kwan, E.; Stewart, B. W.; Mechetner, E. B.; Gudkov, A. V.; Roninson, I. B. Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int. Natl. Cancer. 1996, 65, 613-619.
26. de Graaf, D.; Sharma, R. C.; Mechetner, E. B.; Schimke, R. T.; Roninson, I. B. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 1238-1242.
27. Vore, M.; Hoffman, T.; Gosland, M. ATP-dependent transport of beta-estradiol 17-(beta-D-glucuronide) in rat canalicular membrane vesicles. Am. J. Physiol. 1996, 277, G791-G798.
28. Higgins, C. F.; Gottesman, M. M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 1992, 17, 18-21.
29. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7735-7738.
30. Sugawara, I.; Hamada, H.; Tsuruo, T.; Mon, S. Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn. J. Cancer Res. 1990, 81, 727-730.
31. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 695-698.
32. Simons, N. L.; Hunter, J.; Jepson, M. A. Renal secretion of xenobiotics mediated by P-glycoprotein: Importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease. Adv. Drug Deliv. Rev. 1997, 25, 243-256.
33. Hunter, J.; Hirst, B. H. Intestinalsecretion of drugs. The role of P-glycoprotein and related drug efflux sstems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 1997, 25, 129-157.
34. Tsuji, A.; Tamai, I. Blood-brain barrier function of P-glycoprotein. Adv. Drug Deliv. Rev. 1997, 25, 285-298.
35. Zaman, G. J.; Flens, M. J.; van Leusden, M. R.; de Haas, M.; Mulder, H. S.; Lankelma, J.; Pinedo, H. M.; Scheper, R. J.; Baas, F.; Broxterman, H. J.; Borst, P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8822-8826.
36. Ruetz, S.; Brault, M.; Kast, C.; Hemenway, C.; Heitman, J.; Grant, C. E.; Cole, S. P.; Deeley, R. G.; Gros, P. Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 1996, 271, 4154-4160.
37. Cole, S. P. C.; Sparks, K. E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54, 5902-5910.
38. Breuninger, L. M.; Paul, S.; Gaughan, K.; Miki, T.; Chan, A.; Aaronson, S. A.; Kruh, G. D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995, 55, 5342-5347.
39. Evers, R.; Zaman, G. J.; van Deemter, L.; Jansen, H.; Calafat, J.; Oomen, L. C.; Oude Elferink, R. P. J.; Borst, P.; Schinkel, A. H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 1996, 97, 1211-1218.
40. Jedlitschky, G.; Leier, I.; Buchholz, U.; Barnouin, K.; Kurz, G.; Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56, 988-994.
41. McGrath, T.; Latoud, C.; Arnold, S. T.; Safa, A. R.; Felsted, R. L.; Center, M. S. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol. 1989, 38, 3611-3619.
42. Krishnamachary, N.; Center, M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993, 53, 3658-3661.
43. Loe, D. W.; Almquist, K. C.; Deeley, R. G.; Cole, S. P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 1996, 271, 9675-9682.
44. Zaman, G. J.; Lankelma, J.; van Tellingen, O.; Beijnen, J.; Dekker: H.; Paulusma, C.; Oude Elferink, R. P. J.; Baas, F.; Borst, P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7690-7694.
45. Versantvoort, C. H.; Broxterman, H. J.; Bagrij, T.; Scheper, R. J.; Twentyman, P. R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br. J. Cancer 1995, 72, 82-89.
46. Paul, S.; Breuninger, L. M.; Tew, K. D.; Shen, H. X.; Kruh, G. D. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter (Vol. 93, p 6929, 1996). Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14976.
47. Shen, H. X.; Paul, S.; Breuninger, L. M.; Ciaccio, P. J.; Laing, N. M.; Helt, M.; Tew, K. D.; Kruh, G. D. Cellular and in vitro transport of glutathione conjugates by MRP (Vol. 35, p 5719, 1996). Biochemistry 1997, 36, 13972.
48. Leier, I.; Jedlitschky, G.; Buchholz, U.; Cole, S. P.; Deeley, R. G.; Keppler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 1994, 269, 27807-27810.
49. Jedlitschky, G.; Leier, I.; Buchholz, U.; Center, M.; Keppler, D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994, 54, 4833-4836.
50. Muller, M.; Meijer, C.; Zaman, G. J.; Borst, P.; Scheper, R. J.; Mulder, N. H.; de Vries, E. G.; Jansen, P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 13033-13037.
51. Ishikawa, T.; Bao, J. J.; Yamane, Y.; Akimaru, K.; Frindrich, K.; Wright, C. D.; Kuo, M. T. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem. 1996, 271, 14981-14988.
52. Zaman, G. J.; Cnubben, N. H.; van Bladeren, P. J.; Evers, R.; Borst, P. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Lett. 1996, 391, 126-130.
53. Loe, D. W.; Stewart, R. K.; Massey, T. E.; Deeley, R. G.; Cole, S. P. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. 1997, 51, 1034-1041.
54. Loe, D. W.; Almquist, K. C.; Cole, S. P.; Deeley, R. G. ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem. 1996, 271, 9683-9689.
55. Li, Z. S.; Szczypka, M.; Lu, Y. P.; Thiele, D. J.; Rea, P. A. The yeast cadmium factor protein (YCF1) is a vacuolar glutathione S-conjugate pump. J. Biol. Chem. 1996, 277, 6509-6517.
56. Tommasini, R.; Evers, R.; Vogt, E.; Mornet, C.; Zaman, G. J.; Schinkel, A. H.; Borst, P.; Martinoia, E. The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6743-6748.
57. Li, Z. S.; Lu, Y. P.; Zhen, R. G.; Szczypka, M.; Thiele, D. J.; Rea, P. A. A new pathway for vacuolar cadmium sequestration in Saccharomyces cerevisiae: YCF1-catalyzed transport of bis(glutathionato)cadmium. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 42-47.
58. Ishikawa, T.; Ali-Osman, F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 1993, 268, 20116-20125.
59. Ishikawa, T.; Wright, C. D.; Ishizuka, H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J. Biol. Chem. 1994, 269, 29085-29093.
60. Kuo, M. T.; Bao, J. J.; Curley, S. A.; Ikeguchi, M.; Johnston, D. A.; Ishikawa, T. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res. 1996, 56, 3642-3644.
61. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. 1992, 17, 463-468.
62. Wijnholds, J.; Evers, R.; van Leusden, M. R.; Mol, C. A.; Zaman, G. J.; Mayer, U.; Beijnen, J. H.; van der Valk, M.; Krimpenfort, P.; Borst, P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Medicine 1997, 3, 1275-1279.
63. Zaman, G. J.; Versantvoort, C. H.; Smit, J. J.; Eijdems, E. W.; de Haas, M.; Smith, A. J.; Broxterman, H. J.; Mulder, N. H.; de Vries, E. G.; Baas, F.; Borst, P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993, 53, 1747-1750.
64. Stride, B. D.; Valdimarsson, G.; Gerlach, J. H.; Wilson, G. M.; Cole, S. P.; Deeley, R. G. Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol. Pharmacol. 1996, 49, 962-971.
65. Flens, M. J.; Zaman, G. J.; van der Valk, P.; Izquierdo, M. A.; Schroeijers, A. B.; Scheffer, G. L.; van der Groep, P.; de Haas, M.; Meijer, C. J.; Scheper, R. J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 1996, 148, 1237-1247.
66. Meijer, D. K. F.; Smit, J. W.; Muller, M. Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters. Adv. Drug Deliv. Rev. 1997, 25, 159-200.
67. Silverman, J. A.; Schrenk, D. Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. FASEB J. 1997, 11, 308-313.
68. Kamimoto, Y.; Gatmaitan, Z.; Hsu, J.; Arias, I. M. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem. 1989, 264, 11693-11698.
69. Watanabe, T.; Miyauchi, S.; Sawada, Y.; Iga, T.; Hanano, M.; Inaba, M.; Sugiyama, Y. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J. Hepatol. 1992, 16, 77-88.
70. Watanabe, T.; Suzuki, H.; Sawada, Y.; Naito, M.; Tsuruo, T.; Inaba, M.; Hanano, M.; Sugiyama, Y. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J. Hepatol. 1995, 23, 440-448.
71. Lum, B. L.; Kaubisch, S.; Yahanda, A. M.; Adler, K. M.; Jew, L.; Ehsan, M. N.; Brophy, N. A.; Halsey, J.; Gosland, M. P.; Sikic, B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 1992, 10, 1635-1642.
72. Lum, B. L.; Gosland, M. P.; Kaubisch, S.; Sikic, B. I. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacother. 1993, 13, 88-109.
73. Tsuruo, T.; Tomida, A. Multidrug resistance. Anti-Cancer Drugs 1995, 6, 213-218.
74. Beck, W. T. In In Molecular and Clinical Advances in Anticancer Drug Resistance.; Ozols, R. F., Ed.; Kluwer: Boston, 1991; pp 151-170.
75. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155-199.
76. Ford, J. M. Modulators of multidrug resistance. Preclinical studies. Hematol. Oncol. Clin. North America 1995, 9, 337-361.
77. Gottesman, M. M.; Mickisch, G. H.; Pastan, I. In vivo models of P-glycoprotein-mediated multidrug resistance. Cancer Treat. Res. 1994, 73, 107-128.
78. Keller, R. P.; Altermatt, H. J.; Donatsch, P.; Zihlmann, H.; Laissue, J. A.; Hiestand, P. C. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. Natl. Cancer 1992, 51, 433-438.
79. Watanabe, T.; Tsuge, H.; Oh-Hara, T.; Naito, M.; Tsuruo, T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncologica 1995, 34, 235-241.
80. Raderer, M.; Scheithauer, W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993, 72, 3553-3563.
81. Boote, D. J.; Dennis, I. F.; Twentyman, P. R.; Osborne, R. J.; Laburte, C.; Hensel, S.; Smyth, J. F.; Brampton, M. H.; Bleehen, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 1996, 14, 610-618.
82. Bohme, M.; Jedlitschky, G.; Leier, I.; Buchler, M.; Keppler, D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv. Enzyme Regul. 1994, 34, 371-380.
83. Horton, J. K.; Thimmaiah, K. N.; Houghton, J. A.; Horowitz, M. E.; Houghton, P. J. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem. Pharmacol. 1989, 38, 1727-1736.
84. Colombo, T.; Gonzalez Paz, O.; D'Incalci, M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br. J. Cancer 1996, 73, 866-871.
85. Lum, B. L.; Gosland, M. P. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North America 1995, 9, 319-336.
86. Leveque, D.; Jehl, F. P-glycoprotein and pharmacokinetics. Anticancer Res. 1995, 15, 331-336.
87. Speeg, K. V.; Maldonado, A. L. Effect of the nonimmunosuppressive cyclosporin analogue SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol. 1994, 34, 133-136.
88. Lyubimov, E.; Lan, L. B.; Pashinsky, I.; Stein, W. D. Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anti-Cancer Drugs 1996, 7, 60-69.
89. Arboix, M.; Paz, O. G.; Colombo, T.; Dincalci, M. Multidrug resistance reversing agents increase vinblastine distribution in normal tissues expressing the p glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther. 1997, 281, 1226-1230.
90. Gonzalez, O.; Colombo, T.; De Fusco, M.; Imperatori, L.; Zucchetti, M.; D'Incalci, M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol. 1995, 36, 335-340.
91. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
92. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13, 129-134.
93. Schuetz, E. G.; Beck, W. T.; Schuetz, J. D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 1996, 49, 311-318.
94. Schuetz, E. G.; Schinkel, A. H.; Relling, M. V.; Schuetz, J. D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 4001-4005.
95. Thorgeirsson, S. S.; Silverman, J. A.; Gant, T. W.; Marino, P. A. Multidrug resistance gene family and chemical carcinogens. Pharmacol. Ther. 1991, 49, 283-292.
96. Schmidt, J. V.; Bradfield, C. A. Ah receptor signaling pathways. Annu. Rev. Cell Dev. Biol. 1996, 12, 55-89.
97. Vollrath, V.; Wielandt, A. M.; Acuna, C.; Duarte, I.; Andrade, L.; Chianale, J. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J. Hepatol. 1994, 21, 754-763.
98. Burt, R. K.; Thorgeirsson, S. S. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J. Natl. Cancer Inst. 1988, 80, 1383-1386.
99. Gant, T. W.; Silverman, J. A.; Bisgaard, H. C.; Burt, R. K.; Marino, P. A.; Thorgeirsson, S. S. Regulation of 2-acetylaminofluorene- and 3-methylcholanthrene-mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol. Carcinog. 1991, 4, 499-509.
100. Hill, B. A.; Brown, P. C.; Preisegger, K. H.; Silverman, J. A. Regulation of mdr1b gene expression in Fischer, Wistar and Sprague-Dawley rats in vivo and in vitro. Carcinogenesis 1996, 17, 451-457.
101. Thorgeirsson, S. S.; Huber, B. E.; Sorrell, S.; Fojo, A.; Pastan, I.; Gottesman, M. M. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987, 236, 1120-1122.
102. Teeter, L. D.; Estes, M.; Chan, J. Y.; Atassi, H.; Sell, S.; Becker, F. F.; Kuo, M. T. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol. Carcinog. 1993, 8, 67-73.
103. Nakatsukasa, H.; Silverman, J. A.; Gant, T. W.; Evarts, R. P.; Thorgeirsson, S. S. Expression of multidrug resistance genes in rat liver during regeneration and after carbon tetrachloride intoxication. Hepatology (St. Louis) 1993, 18, 1202-1207.
104. Schrenk, D.; Gant, T. W.; Preisegger, K. H.; Silverman, J. A.; Marino, P. A.; Thorgeirsson, S. S. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatolpgy (St. Louis) 1993, 17, 854-860.
105. Marino, P. A.; Gottesman, M. M.; Pastan, I. Regulation of the multidrug resistance gene in regenerating rat liver. Cell Growth Different. 1990, 1, 57-62.
106. Orr, G. A.; Han, E. K.; Browne, P. C.; Nieves, E.; O'Connor, B. M.; Yang, C. P.; Horwitz, S. B. Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites. J. Biol. Chem. 1993, 268, 25054-25062.
107. Chambers, T. C.; Pohl, J.; Raynor, R. L.; Kuo, J. F. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J. Biol. Chem. 1993, 268, 4592-4595.
108. Chambers, T. C.; Zheng, B.; Kuo, J. F. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol. Pharmacol. 1992, 41, 1008-1015.
109. Ahmad, S.; Glazer, R. I. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol. 1993, 43, 858-862.
110. Bates, S. E.; Lee, J. S.; Dickstein, B.; Spolyar, M.; Fojo, A. T. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 1993, 32, 9156-9164.
111. Chaudhary, P. M.; Roninson, I. B. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol. Res. 1992, 4, 281-290.
112. Sato, W.; Yusa, K.; Naito, M.; Tsuruo, T. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 1990, 173, 1252-1257.
113. Germann, U. A.; Chambers, T. C.; Ambudkar, S. V.; Licht, T.; Cardarelli, C. O.; Pastan, I.; Gottesman, M. M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J. Biol. Chem. 1996, 271, 1708-1716.
114. Oude Elferink, R. P.; Ottenhoff, R.; van Wijland, M.; Smit, J. J.; Schinkel, A. H.; Groen, A. K. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J. Clin. Invest. 1995, 95, 31-38.
115. Smit, J. J.; Schinkel, A. H.; Oude Elferink, R. P. J.; Groen, A. K.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; Ottenhoff, R.; van der Lugt, N. M.; van Roon, M. A.; van der Valk, M. A.; Offerhaus, G. J.; Berns, A. J. M.; Borst, P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75, 451-462.
116. Ruetz, S.; Gros, P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994, 77, 1071-1081.
117. van Helvoort, A.; Smith, A. J.; Sprong, H.; Fritzsche, I.; Schinkel, A. H.; Borst, P.; van Meer, G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996, 87, 507-517.
118. Oude Elferink, R. P.; Groen, A. K. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J. Hepatol. 1995, 23, 617-625.
119. Frijters, C. M. G.; Groen, A. K.; Oude Elferink, R. P. J. MDR2 P-glycoprotein-mediated lipid secretion and its relevance to biliary drug transport. Adv. Drug Deliv. Rev. 1997, 25, 201-215.
120. Coleman, R.; Rahman, K.; Kan, K. S.; Parslow, R. A. Retrograde intrabiliary injection of amphipathic materials causes phospholipid secretion into bile. Taurocholate causes phosphatidylcholine secretion, 3-[(3-cholamidopropyl)dimethylammonio]-propane-1-sulphonate (CHAPS) causes mixed phospholipid secretion. Biochem. J. 1989, 258, 17-22.
121. Ruetz, S.; Gros, P. Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. J. Biol. Chem. 1995, 270, 25388-25395.
122. Yamazaki, M.; Suzuki, H.; Sugiyama, Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 1996, 13, 497-513.
123. Keppler, D.; Kartenbeck, J. The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Progr. Liver Dis. 1996, 14, 55-67.
124. Muller, M.; Roelofsen, H.; Jansen, P. L. Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Semin. Liver Dis. 1996, 16, 211-220.
125. Kuipers, F.; Enserink, M.; Havinga, R.; van der Steen, A. B.; Hardonk, M. J.; Fevery, J.; Vonk, R. J. Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat. J. Clin. Invest. 1988, 81, 1593-1599.
126. Jansen, P. L.; Peters, W. H.; Lamers, W. H. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology (St. Louis) 1985, 5, 573-579.
127. Mikami, T.; Nozaki, T.; Tagaya, O.; Hosokawa, S.; Nakura, T.; Hori, H.; Kondou, S. Congr. Anom. 1986, 26, 250-251.
128. Hosokawa, S.; Tagaya, O.; Mikami, T.; Nozaki, Y.; Kawaguchi, A.; Yamatsu, K.; Shamoto, M. A new rat mutant with chronic conjugated hyperbilirubinemia and renal glomerular lesions. Lab Ani. Sci. 1992, 42, 27-34.
129. Dubin, I. N.; Johnson, F. B. Chronic idiopathic jaundice with unidentified pigment in liver cells: a new clinicopathologic entity with a report of 12 cases. Medicine 1954, 33, 155-172.
130. Keppler, D.; Arias, I. M. Hepatic canalicular membrane. Introduction: transport across the hepatocyte canalicular membrane. FASEB J. 1997, 11, 15-18.
131. Keppler, D.; Leier, I.; Jedlitschky, G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 1997, 378, 787-791.
132. Muller, M.; Jansen, P. L. Molecular aspects of hepatobiliary transport. Am. J. Physiol. 1997, 272, G1285-G1303.
133. Kobayashi, K.; Sogame, Y.; Hara, H.; Hayashi, K. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J. Biol. Chem. 1990, 265, 7737-7741.
134. Ishikawa, T.; Muller, M.; Klunemann, C.; Schaub, T.; Keppler, D. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J. Biol. Chem. 1990, 265, 19279-19286.
135. Roelofsen, H.; Vos, T. A.; Schippers, I. J.; Kuipers, F.; Koning, H.; Moshage, H.; Jansen, P. L.; Muller, M. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997, 112, 511-521.
136. Paulusma, C. C.; Oude Elferink, R. P. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med. 1997, 75, 420-428.
137. Oude Elferink, R. P.; Frijters, C. M.; Paulusma, C.; Groen, A. K. Regulation of canalicular transport activities. J. Hepatol. 1996, 24, 94-99.
138. Muller, M.; de Vries, E. G.; Jansen, P. L. Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells. J. Hepatol. 1996, 24, 100-108.
139. Takenaka, O.; Horie, T.; Kobayashi, K.; Suzuki, H.; Sugiyama, Y. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. 1995, 12, 1746-1755.
140. Chu, X. Y.; Kato, Y.; Niinuma, K.; Sudo, K. I.; Hakusui, H.; Sugiyama, Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 1997, 281, 304-314.
141. Chu, X. Y.; Kato, Y.; Sugiyama, Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 1997, 57, 1934-1938.
142. Takenaka, O.; Horie, T.; Suzuki, H.; Sugiyama, Y. Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther. 1995, 274, 1362-1369.
143. Shimamura, H.; Suzuki, H.; Hanano, M.; Suzuki, A.; Tagaya, O.; Horie, T.; Sugiyama, Y. Multiple systems for the biliary excretion of organic anions in rats: liquiritigenin conjugates as model compounds. J. Pharmacol. Exp. Ther. 1994, 271, 370-378.
144. Shimamura, H.; Suzuki, H.; Tagaya, O.; Horie, T.; Sugiyama, Y. Biliary excretion of glycyrrhizin in rats: kinetic basis for multiplicity in bile canalicular transport of organic anions. Pharm. Res. 1996, 13, 1833-1837.
145. Kuipers, F.; Radominska, A.; Zimniak, P.; Little, J. M.; Havinga, R.; Vonk, R. J.; Lester, R. Defective biliary secretion of bile acid 3-O-glucuronides in rats with hereditary conjugated hyperbilirubinemia. J. Lipid Res. 1989, 30, 1835-1845.
146. Sathirakul, K.; Suzuki, H.; Yasuda, K.; Hanano, M.; Tagaya, O.; Hone, T.; Sugiyama, Y. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J. Pharmacol. Exp. Ther. 1993, 265, 1301-1312.
147. Sathirakul, K.; Suzuki, H.; Yamada, T.; Hanano, M.; Sugiyama, Y. Multiple transport systems for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 1994, 268, 65-73.
148. Yamazaki, M.; Kobayashi, K.; Sugiyama, Y. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats. Biopharm. Drug Disp. 1996, 17, 645-659.
149. Ishizuka, H.; Konno, K.; Naganuma, H.; Sasahara, K.; Kawahara, Y.; Niinuma, K.; Suzuki, H.; Sugiyama, Y. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J. Pharmacol. Exp. Ther. 1997, 280, 1304-1311.
150. Masuda, M.; I'Izuka, Y.; Yamazaki, M.; Nishigaki, R.; Kato, Y.; Ni'inuma, K.; Suzuki, H.; Sugiyama, Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 1997, 57, 3506-3510.
151. Shin, H. C.; Kato, Y.; Yamada, T.; Niinuma, K.; Hisaka, A.; Sugiyama, Y. Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. Am. J. Physiol. 1997, 272, G979-G986.
152. Yamada, T.; Niinuma, K.; Lemaire, M.; Terasaki, T.; Sugiyama, Y. Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide. J. Pharmacol. Exp. Ther. 1996, 279, 1357-1364.
153. Jedlitschky, G.; Leier, I.; Buchholz, U.; Hummel-Eisenbeiss, J.; Burchell, B.; Keppler, D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 1997, 327, 305-310.
154. Niinuma, K.; Kato, Y.; Tyson, C. A.; Weizer, V.; Dabbs, J. E.; Froelich, R.; Green, C. E.; Suzuki, H.; Sugiyama, Y. Comparative study of the active transport of organic anions into bile canalicular membrane vesicles isolated from rats and humans. Hepatology (St. Louis) 1997, 26, 1775.
155. Meier, P. J. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am. J. Physiol. 1995, 269, G801-G812.
156. Paulusma, C. C.; Bosma, P. J.; Zaman, G. J.; Bakker, C. T.; Otter, M.; Scheffer, G. L.; Scheper, R. J.; Borst, P.; Oude Elferink, R. P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271, 1126-1128.
157. Ito, K.; Suzuki, H.; Hirohashi, T.; Kume, K.; Shimizu, T.; Sugiyama, Y. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol. 1997, 272, G16-G22.
158. Ito, K.; Suzuki, H.; Hirohashi, T.; Kume, K.; Shimizu, T.; Sugiyama, Y. Expression of the putative ATP-binding cassette region, homologous to that in multidrug resistance associated protein (MRP), is hereditarily defective in Eisai hyperbirilubinemic rats (EHBR). Int. Hepatol. Commun. 1996, 4, 292-299.
159. Buchler, M.; Konig, J.; Brom, M.; Kartenbeck, J.; Spring, H.; Horie, T.; Keppler, D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 1996, 271, 15091-15098.
160. Kitamura, T.; Alroy, J.; Gatmaitan, Z.; Inoue, M.; Mikami, T.; Jansen, P.; Arias, I. M. Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology (St. Louis) 1992, 15, 1154-1159.
161. Ito, K.; Suzuki, H.; Hirohashi, T.; Kume, K.; Shimizu, T.; Sugiyama, Y. Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J. Biol. Chem. 1998, 273, 1684-1688.
162. Madon, J.; Eckhardt, U.; Gerloff, T.; Stieger, B.; Meier, P. J. Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. FEBS Lett. 1997, 406, 75-78.
163. Roelofsen, H.; Ottenhoff, R.; Oude Elferink, R. P.; Jansen, P. L. Hepatocanalicular organic-anion transport is regulated by protein kinase C. Biochem. J. 1991, 278, 637-641.
164. Oude Elferink, R. P.; Bakker, C. T.; Roelofsen, H.; Middelkoop, E.; Ottenhoff, R.; Heijn, M.; Jansen, P. L. Accumulation of organic anion in intracellular vesicles of cultured rat hepatocytes is mediated by the canalicular multispecific organic anion transporter. Hepatology (St. Louis) 1993, 17, 434-444.
165. Trauner, M.; Arrese, M.; Soroka, C. J.; Ananthanarayanan, M.; Koeppel, T. A.; Schlosser, S. F.; Suchy, F. J.; Keppler, D.; Boyer, J. L. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997, 113, 255-264.
166. Kauffmann, H. M.; Keppler, D.; Kartenbeck, J.; Schrenk, D. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology (St. Louis) 1997, 26, 980-985.
167. Taniguchi, K.; Wada, M.; Kohno, K.; Nakamura, T.; Kawabe, T.; Kawakami, M.; Kagotani, K.; Okumura, K.; Akiyama, S.; Kuwano, M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996, 56, 4124-4129.
168. Kool, M.; de Haas, M.; Scheffer, G. L.; Scheper, R. J.; van Eijk, M. J.; Juijn, J. A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
169. Ishikawa, T.; Akimaru, K. In In glutathione S-transferases: structure, function, and clinical implications; Vermeulen, N. P. E., Mulder, G. J., Nieuwenhuyse, H., Peters, W. H. M., van Bladeren, P. J., Eds.; Taylor and Francis: London, 1996; pp 199-211.
170. Koike, K.; Kawabe, T.; Tanaka, T.; Toh, S.; Uchiumi, T.; Wada, M.; Akiyama, S.; Ono, M.; Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997, 57, 5475-5479.
171. Kartenbeck, J.; Leuschner, U.; Mayer, R.; Keppler, D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology (St. Louis) 1996, 23, 1061-1066.
172. Wada, M.; Toh, S.; Taniguchi, K.; Nakamura, T.; Uchiumi, T.; Kohno, K.; Yoshida, I.; Kimura, A.; Sakisaka, S.; Adachi, Y.; Kuwano, M. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 1998, 7, 203-207.
173. Niinuma, K.; Takenaka, O.; Horie, T.; Kobayashi, K.; Kato, Y.; Suzuki, H.; Sugiyama, Y. Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazoleglucuronide. J. Pharmacol. Exp. Ther. 1997, 282, 866-872.
174. Hirohashi, T.; Ito, K.; Suzuki, H.; Kume, K.; Shimizu, T.; Sugiyama, Y. Molecular biological studies on rat novel ABC transporters. Pharm. Res. 1996, 13, S-393.
175. Hirohashi, T.; Niinuma, K.; Ito, K.; Suzuki, H.; Kume, K.; Shimizu, T.; Sugiyama, Y. Characterization of ATP-dependent organic anion transport system on rat canalicular membrane maintained in EHBR. Hepatology (St. Louis) 1996, 24, 203A.
176. Hirohashi, T.; Suzuki, H.; Ito, K.; Ogawa, K.; Kume, K.; Shimizu, T.; Sugiyama, Y. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai Hyperbilirubinemic rats. Mol. Pharmacol. 1998, 53, 1068-1075.
177. Ogawa, K.; Suzuki, H.; Ito, K.; Kume, K.; Shimizu, T.; Sugiyama, Y. Molecular characterization of canalicular multispecific organic anion transporter and its related proteins expressed in rat liver. Pharm. Res. 1997, 14, S-458.
178. Gunn, C. K. Hereditary acholuric jaundice in a new mutant strain of rats. J. Hered. 1938, 29, 137-139.
179. Oude Elferink, R. P.; Bakker, C. T.; Jansen, P. L. Glutathione-conjugate transport by human colon adenocarcinoma cells (Caco-2 cells). Biochem. J. 1993, 290, 759-764.
180. Ishikawa, T.; Kobayashi, K.; Sogame, Y.; Hayashi, K. Evidence for leukotriene C4 transport mediated by an ATP-dependent glutathione S-conjugate carrier in rat heart and liver plasma membranes. FEBS Lett. 1989, 259, 95-98.
181. Ishikawa, T. ATP/Mg2+-dependent cardiac transport system for glutathione S-conjugates. A study using rat heart sarcolemma vesicles. J. Biol. Chem. 1989, 264, 17343-17348.
182. Awasthi, S.; Singhal, S. S.; Srivastava, S. K.; Zimniak, P.; Bajpai, K. K.; Saxena, M.; Sharma, R.; Ziller, S. A. r.; Frenkel, E. P.; Singh, S. V.; et al. Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J. Clin. Invest. 1994, 93, 958-965.
183. Board, P. G. Transport of glutathione S-conjugate from human erythrocytes. FEBS Lett. 1981, 124, 163-165.
184. Board, P.; Nishida, T.; Gatmaitan, Z.; Che, M.; Arias, I. M. Erythrocyte membrane transport of glutathione conjugates and oxidized glutathione in the Dubin-Johnson syndrome and in rats with hereditary hyperbilirubinemia. Hepatology (St. Louis) 1992, 15, 722-725.
185. Leier, I.; Jedlitschky, G.; Buchler, M.; Buchholz, U.; Brom, M.; Keppler, D. Identification of the biosynthetic leukotriene C4 export pump in murine mastocytoma cells as a homologue of the multidrug-resistance protein. Eur. J. Biochem. 1996, 242, 201-205.
186. Kusuhara, H.; Suzuki, H.; Naito, M.; Tsuruo, T.; Sugiyama, Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line (MBEC4). J. Pharmacol. Exp. Ther. 1998, 285, 1260-1265.
187. Suzuki, H.; Terasaki, T.; Sugiyama, Y. Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug Deliv. Rev. 1997, 25, 257-285.
188. Fujita, T.; Yamada, H.; Fukuzumi, M.; Nishimaki, A.; Yamamoto, A.; Muranishi, S. Calcein is excreted from the intestinal mucosal cell membrane by the active transport system. Life Sci. 1997, 60, 307-313.
189. Iwatsubo, T.; Hirota, N.; Ooie, T.; Suzuki, H.; Sugiyama, Y. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Disp. 1996, 17, 273-310.
190. Iwatsubo, T.; Hirota, N.; Ooie, T.; Suzuki, H.; Shimada, N.; Chiba, K.; Ishizaki, T.; Green, C. E.; Tyson, C. A.; Sugiyama, Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 1997, 73, 147-171.
191. Iwatsubo, T.; Suzuki, H.; Shimada, N.; Chiba, K.; Ishizaki, T.; Green, C. E.; Tyson, C. A.; Yokoi, T.; Kamataki, T.; Sugiyama, Y. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J. Pharmacol. Exp. Ther. 1997, 282, 909-919.